Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.83)
# 3,019
Out of 4,829 analysts
62
Total ratings
45.45%
Success rate
-5.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $59.64 | +10.66% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $34.68 | -36.56% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $5.70 | +163.16% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $18.46 | +149.19% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $11.04 | +63.04% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $1.31 | +283.14% | 3 | Mar 15, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $5.95 | +118.49% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $35.46 | -21.04% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $46.12 | +12.75% | 5 | Nov 29, 2023 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.51 | +4,138.41% | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $23 | $0.83 | +2,677.78% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $1.27 | +1,553.54% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $3.07 | +356.03% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $29.36 | -72.75% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.27 | +5,901.50% | 2 | Dec 15, 2021 |
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $59.64
Upside: +10.66%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $34.68
Upside: -36.56%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $5.70
Upside: +163.16%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $18.46
Upside: +149.19%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $11.04
Upside: +63.04%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $1.31
Upside: +283.14%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $5.95
Upside: +118.49%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $35.46
Upside: -21.04%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $46.12
Upside: +12.75%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.51
Upside: +4,138.41%
Mar 15, 2023
Maintains: Buy
Price Target: $27 → $23
Current: $0.83
Upside: +2,677.78%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.27
Upside: +1,553.54%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $3.07
Upside: +356.03%
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $29.36
Upside: -72.75%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.27
Upside: +5,901.50%